Menu
Contact us

Non-invasive delivery technologies

Drug delivery platforms for the non-invasive administration of peptides, proteins, and nucleic acids. Leveraging thiomer and SEDDS platforms, we support pharma and biotech partners from concept to clinic.

Our ambition: Far beyond drug delivery

ThiomersSEDDS

The drug delivery network

ThioMatrix specializes in the development of non-invasive drug delivery systems, leveraging its core technologies: Thiomer Technology and Self-Emulsifying Drug Delivery Systems (SEDDS) Technology. These cutting-edge platforms offer significant potential to enhance the efficacy of non-invasively administered:

  • therapeutic peptides

  • peptidomimetics

  • nucleotides (DNA- and RNA-based drugs) 

  • Class II, III and IV drugs under the Biopharmaceutical Classification System (BCS)

  • drugs that are substrates of efflux pumps, such as anticancer agents

By harnessing the power of these technologies, we can significantly improve bioavailability and therapeutic outcomes.

ThioMatrix has established a robust network of partnerships and collaborations with hospitals, veterinary institutions, CROs, and universities. This comprehensive network supports the full development pipeline—from preclinical research through to clinical trials. Combined with our proprietary technologies and in-house expertise, this integrated approach enables us to accelerate time to market and develop optimal delivery systems tailored to your therapeutic candidates.

To explore our drug delivery technologies and review results from various in vivo studies and clinical trials, please visit the Technologies section of our website.

20+
years of experience
10+
Co-workers
World map highlighting countries in blue and a marked location with a red pin in Germany. Gray indicates unhighlighted areas.
100+
Collaborations
500+
Performed projects
Stylized blue silhouette of a mountain range against a white background.
Innsbruck
Heart of the alps
5+
Awards
10+
Project grants

Latest news

A stylized "Daedalus" logo with a blue cloud-like shape and an extended tail creating a shadow effect on a white background.

Daedalus project

ThioMatrix is part of the EU-project daedalus
News
Trends

TENTACLE project

In January 2025 Thiomatrix joined the EU-project TENTACLE ((101191747). This project aims to develop a novel strategy to replace intestinal mucosa and submucosa of patients who underwent proctocolectomy.
News

Science Award of Tyrol 2023

Prof. Dr. Andreas Bernkop-Schnürch, CSO ThioMatrix, received the Science Award of Tyrol 2023 for his pioneerung reseacrh on thiolated polymers (=thiomers) that are meanwhile used in numerous pharmaceutical and medicinal products.

Events

Discovery & Development Europe 2025: Formulation & Drug Delivery Congress

Invited lecture: Oral Delivery Of Peptide And Protein Drugs – Oral Delivery of GLP-1 Analogues, Prof. Dr. A. Bernkop-Schnürch, Basel, Switzerland

8th European Cyclodextrin Conference

Invited lecture: Thiolated Cyclodextrins in Drug Delivery, Prof. Dr. A. Bernkop-Schnürch, Milano, Italy
A large group of people standing on a staircase, posing for a photo. Many are wearing name tags and dressed in business casual attire.

Daedalus - Kick-off meeting

The DAEDALUS project officially kicked off with a two-day meeting held in Pisa, Italy, gathering all consortium partners and the Project Officer from the European Commission. The event marked the formal launch of a four-year European research initiative focused on developing minimally invasive therapies for colorectal diseases using smart, responsive 4D biomaterials.
A group of people standing on a staircase inside a modern building, smiling and posing for a photo.

TENTACLE - Kick-off meeting

TENTACLE is an ambitious EU-funded project and has officially launched with its kick-off meeting in Würzburg, bringing together leading scientists, surgeons, and medical experts from across Europe. With a strong focus on minimally invasive surgery, in-situ 4D bioprinting and precision medicine, TENTACLE aims to revolutionize colorectal disease treatment by reducing patient trauma and improving surgical outcomes that are one of the major struggles for patients. The two-day meeting served as a crucial starting point for defining project milestones, research strategies, and collaborative efforts. Discussions covered all kind of topics: from the integration of 4D bioprinting technologies into endoscopic procedures to the roadmap for clinical validation.
A group of people pose in a conference room, with a presentation screen and several framed portraits on the walls.

TENTACLE - Progress meeting 1

The TENTACLE consortium met in Pisa for its first progress meeting (M6), hosted by the University of Pisa. This in-person meeting marked a key moment to take stock of the work conducted in the first six months of the project and to coordinate on the activities ahead.
A group of people posing in a conference room, with laptops and a presentation screen in the background. Video call participants are visible on a screen.

TENTACLE - Progress meeting 2

The TENTACLE consortium met in Pisa for its first progress meeting (M6), hosted by the University of Pisa. This in-person meeting marked a key moment to take stock of the work conducted in the first six months of the project and to coordinate on the activities ahead.

Contact us and talk to our experts

Highly skilled and compassionate professionals ready to care for you

Contact us